Intercept Pharma (ICPT) Announces Dagmar Rosa-Bjorkeson to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Intercept Pharma (ICPT) Misses Q4 EPS by 11c, Revenues Miss
February 25, 2021 7:29 AM ESTIntercept Pharma (NASDAQ: ICPT) reported Q4 EPS of ($1.58), $0.11 worse than the analyst estimate of ($1.47). Revenue for the quarter came in at $83.27 million versus the consensus estimate of $85.01 million.
As we turn the page on 2020, I am proud of the Intercept teams efforts to... More
UPDATE: H.C. Wainwright Downgrades Intercept Pharmaceuticals (ICPT) to Sell
February 23, 2021 6:47 AM EST(Updated - February 23, 2021 7:01 AM EST)
H.C. Wainwright analyst Ed Arce downgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Neutral to Sell, PT $25.00.
The analyst comments "In short, we no longer believe a viable regulatory path for OCA exists in... More
Intercept Pharma (ICPT) Chief Medical Officer Jason Campagna Resigns to Pursue Other Opportunities
February 22, 2021 4:53 PM ESTIntercept Pharma (NASDAQ: ICPT) disclosed:
On February 18, 2021, Jason Campagna, M.D., Ph.D., notified Intercept Pharmaceuticals, Inc. (the Company) of his decision to resign from his position as the Companys Chief Medical Officer, effective March 5, 2021, in order to pursue other opportunities. Dr.... More
